52 related articles for article (PubMed ID: 19716382)
21. Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo.
Rodrigues EG; Garofalo AS; Travassos LR
Cytokines Cell Mol Ther; 2002; 7(3):107-16. PubMed ID: 12850810
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
23. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
24. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
25. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
26. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
[TBL] [Abstract][Full Text] [Related]
28. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
29. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
30. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
31. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
[TBL] [Abstract][Full Text] [Related]
32. Induction of potent antitumor response by vaccination with tumor lysate-pulsed macrophages engineered to secrete macrophage colony-stimulating factor and interferon-gamma.
Lei H; Ju DW; Yu Y; Tao Q; Chen G; Gu S; Hamada H; Cao X
Gene Ther; 2000 Apr; 7(8):707-13. PubMed ID: 10800095
[TBL] [Abstract][Full Text] [Related]
33. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma interferon plus tumor necrosis factor alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis.
Young MR; Wright MA
Cancer Res; 1992 Nov; 52(22):6335-40. PubMed ID: 1423279
[TBL] [Abstract][Full Text] [Related]
34. Trimerization of murine TNF ligand family member LIGHT increases the cytotoxic activity against the FM3A mammary carcinoma cell line.
Ito T; Iwamoto K; Tsuji I; Tsubouchi H; Omae H; Sato T; Ohba H; Kurokawa T; Taniyama Y; Shintani Y
Appl Microbiol Biotechnol; 2011 Jun; 90(5):1691-9. PubMed ID: 21400099
[TBL] [Abstract][Full Text] [Related]
35. Effective expression and purification of bioactive recombinant soluble LIGHT.
Tsuji I; Iwamoto K; Shintani Y
Methods Mol Biol; 2014; 1155():201-13. PubMed ID: 24788184
[TBL] [Abstract][Full Text] [Related]
36. Engineered Human Ferritin Nanoparticles for Direct Delivery of Tumor Antigens to Lymph Node and Cancer Immunotherapy.
Lee BR; Ko HK; Ryu JH; Ahn KY; Lee YH; Oh SJ; Na JH; Kim TW; Byun Y; Kwon IC; Kim K; Lee J
Sci Rep; 2016 Oct; 6():35182. PubMed ID: 27725782
[TBL] [Abstract][Full Text] [Related]
37. Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma.
Jazowiecka-Rakus J; Sochanik A; Hadryś A; Fidyk W; Chmielik E; Rahman MM; McFadden G
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454928
[TBL] [Abstract][Full Text] [Related]
38. Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma.
Christie JD; Appel N; Zhang L; Lowe K; Kilbourne J; Daggett-Vondras J; Elliott N; Lucas AR; Blattman JN; Rahman MM; McFadden G
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053501
[TBL] [Abstract][Full Text] [Related]
39. The promise and challenges of immune agonist antibody development in cancer.
Mayes PA; Hance KW; Hoos A
Nat Rev Drug Discov; 2018 Jul; 17(7):509-527. PubMed ID: 29904196
[TBL] [Abstract][Full Text] [Related]
40. LIGHT protein suppresses tumor growth by augmentation of immune response.
Morishige T; Yoshioka Y; Inakura H; Tanabe A; Watanabe H; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Immunol Lett; 2009 Dec; 127(1):33-8. PubMed ID: 19716382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
